Medtronic MDT Cardiovascular — Research and development expense
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Medtronic in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost.
The official record: Medtronic’s 10-K, filed June 18, 2026, on SEC EDGAR. View the filing →
Ask your AI about Medtronic's cardiovascular — research and development expense.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Medtronic's cardiovascular — research and development expense?
- Medtronic (MDT) reported cardiovascular — research and development expense of $273M in Q1 2026.
- How has Medtronic's cardiovascular — research and development expense changed year-over-year?
- Medtronic's cardiovascular — research and development expense increased by 5.4% year-over-year, from $259M to $273M.
- What is the long-term trend for Medtronic's cardiovascular — research and development expense?
- Over 3 years (2023 to 2026), Medtronic's cardiovascular — research and development expense has grown at a 11.7% compound annual growth rate (CAGR), from $815M to $1.14B.
- What does cardiovascular — research and development expense mean?
- The total spending on research and development activities specifically for the cardiovascular product segment.
- How do you interpret cardiovascular — research and development expense?
- An increase suggests a focus on future product innovation, while a decrease may indicate cost-cutting or a shift in strategic R&D priorities.
- How does cardiovascular — research and development expense compare across companies?
- Comparable to R&D spending in specialized medical technology segments at peers like Abbott or Boston Scientific.